You have 9 free searches left this month | for more free features.
Clincosm LogoSign in Get a demo

Dual Inhibitor of MET and VEGFR

Showing 1 - 25 of >10,000
STUDY
CONDITIONS
INTERVENTIONS
LOCATIONS
LAST UPDATED

Refractory Soft Tissue Sarcomas Trial run by the NCI (Cabozantinib)

Active, not recruiting
Has Results
  • Refractory Soft Tissue Sarcomas
  • Bethesda, Maryland
    National Institutes of Health Clinical Center, 9000 Rockville Pi
Dec 5, 2022

Recurrent Lung Non-Small Cell Carcinoma, Stage IV Lung Cancer AJCC v8 Trial (procedure, biological, drug)

Not yet recruiting
  • Recurrent Lung Non-Small Cell Carcinoma
  • Stage IV Lung Cancer AJCC v8
  • Biospecimen Collection
  • +5 more
  • (no location specified)
Sep 7, 2023

Adenocarcinoma, Pancreatic Tumors Trial in Saint Louis, Nashville (X-82, Everolimus)

Terminated
Has Results
  • Adenocarcinoma
  • Pancreatic Neoplasms
  • Saint Louis, Missouri
  • +1 more
Jun 15, 2021

Thymic Carcinoma, NSCLC, Refractory Thoracic Tumors Trial in United States (VEGFR/PDGFR Dual Kinase Inhibitor X-82, Nivolumab)

Active, not recruiting
  • Thymic Carcinoma
  • +3 more
  • VEGFR/PDGFR Dual Kinase Inhibitor X-82
  • Nivolumab
  • Palo Alto, California
  • +6 more
Sep 21, 2022

Sarcoma, Stomach Tumors, Tumors Trial run by the NCI (Pazopanib, ARQ 197)

Completed
  • Sarcoma
  • +2 more
  • Bethesda, Maryland
    National Institutes of Health Clinical Center, 9000 Rockville Pi
Jun 23, 2021

Advanced Malignant Tumor, BRAF Gene Mutation, Metastatic Malignant Tumor Trial in Houston (Crizotinib, Laboratory Biomarker

Completed
  • Advanced Malignant Neoplasm
  • +4 more
  • Houston, Texas
    M D Anderson Cancer Center
Jan 19, 2021

Adenoid Cystic Carcinoma, Metastatic Adenoid Cystic Carcinoma, Recurrent Adenoid Cystic Carcinoma Trial in Boston (CB-103,

Not yet recruiting
  • Adenoid Cystic Carcinoma
  • +2 more
  • Boston, Massachusetts
    Dana Farber Cancer Institute
Mar 14, 2023

Lung Cancer Trial in Canada (MET/VEGFR2 inhibitor Foretinib, erlotinib HCl, laboratory biomarker analysis)

Completed
  • Lung Cancer
  • MET/VEGFR2 inhibitor Foretinib
  • +2 more
  • Vancouver, British Columbia, Canada
  • +3 more
Apr 6, 2020

Sarcoma Trial in Shanghai (Apatinib monotherapy)

Recruiting
  • Sarcoma
  • Apatinib monotherapy
  • Shanghai, Shanghai, China
    Ruijin Hospital Shanghai Jiao Tong University School of Medicine
May 18, 2022

Papillary Renal Cell Carcinoma Type 2 Trial in France (Axitinib Oral Tablet [Inlyta], Pembrolizumab Injection [Keytruda])

Recruiting
  • Papillary Renal Cell Carcinoma Type 2
  • Axitinib Oral Tablet [Inlyta]
  • Pembrolizumab Injection [Keytruda]
  • Angers, France
  • +11 more
Aug 26, 2022

Solid Tumor Trial in Madison (drug, other, procedure)

Completed
  • Unspecified Adult Solid Tumor, Protocol Specific
  • VEGFR/PDGFR dual kinase inhibitor X-82
  • +5 more
  • Madison, Wisconsin
    University of Wisconsin-Carbone Cancer Center
Nov 14, 2019

Solid Tumors Trial in France, Italy, Spain (Lucitanib)

Completed
  • Solid Tumors
  • Villejuif, Paris, France
  • +3 more
Jan 2, 2020

Colorectal Cancer, Colorectal Adenocarcinoma Trial in Houston (Brivanib, Irinotecan)

Terminated
Has Results
  • Colorectal Cancer
  • Colorectal Adenocarcinoma
  • Houston, Texas
    UT MD Anderson Cancer Center
Sep 1, 2020

Unresectable Locally Advanced or Metastatic Pancreatic Cancer Trial in Shanghai (surufatinib, KN046, gemcitabine)

Not yet recruiting
  • Unresectable Locally Advanced or Metastatic Pancreatic Cancer
  • Shanghai, Shanghai, China
    Zhongshan Hospital
Apr 16, 2023

Recurrent Head Neck Cancer, Recurrent Head and Neck Squamous Cell Carcinoma, Recurrent Head and Neck Carcinoma Trial in Saint

Not yet recruiting
  • Recurrent Head and Neck Cancer
  • +5 more
  • Saint Louis, Missouri
    Washington University School of Medicine
Jul 30, 2023

Urothelial Cancer Trial in Spain (Niraparib plus Cabozantinib)

Recruiting
  • Urothelial Cancer
  • Niraparib plus Cabozantinib
  • Barcelona, Cataluña, Spain
  • +10 more
Feb 8, 2022

Ovarian Cancer, Ovarian Carcinoma, Platinum-resistant Ovarian Cancer Trial (Pamiparib, Surufatinib)

Not yet recruiting
  • Ovarian Cancer
  • +4 more
  • (no location specified)
Aug 8, 2022

NSCLC Trial in Worldwide (Tepotinib, Osimertinib)

Active, not recruiting
  • Non-small Cell Lung Cancer
  • Yuma, Arizona
  • +178 more
Dec 19, 2022

Gastric Cancer Trial (Fruquintinib+PD-1)

Not yet recruiting
  • Gastric Cancer
  • (no location specified)
Feb 1, 2023

Nasopharyngeal Carcinoma Trial in Guangzhou (Apatinib, Camrelizumab, Chemotherapy (gemcitabine/ capecitabine/ docetaxel),

Not yet recruiting
  • Nasopharyngeal Carcinoma
  • Apatinib, Camrelizumab, Chemotherapy (gemcitabine/ capecitabine/ docetaxel)
  • +3 more
  • Guangzhou, Guangdong, China
    Department of Nasopharyngeal Carcinoma, Sun Yat-sen University C
Sep 17, 2022

Oesophageal Adenocarcinoma, Gastric Adenocarcinoma Trial in France (Capmatinib, Spartalizumab)

Suspended
  • Oesophageal Adenocarcinoma
  • Gastric Adenocarcinoma
  • Besançon, France
  • +6 more
Feb 1, 2023

Intracranial Aneurysm, Stent Complication Trial (Ticagrelor monotherapy, Dual Antiplatelet Therapy)

Not yet recruiting
  • Intracranial Aneurysm
  • Stent Complication
  • Ticagrelor monotherapy
  • Dual Antiplatelet Therapy
  • (no location specified)
Aug 23, 2023

Gastric Cancer Trial in Zhengzhou (fruquintinib + sintilimab + SOX)

Not yet recruiting
  • Gastric Cancer
  • fruquintinib + sintilimab + SOX
  • Zhengzhou, Henan, China
  • +1 more
Dec 15, 2021

Ovarian Cancer Trial (JPI-547)

Not yet recruiting
  • Ovarian Cancer
  • (no location specified)
Jul 24, 2022

Solid Tumor Trial in Bengbu (SPH 3348)

Recruiting
  • Solid Tumor
  • SPH 3348
  • Bengbu, Anhui, China
    The First Affliated Hospital of Bengbu Medical College
Jul 25, 2022